Newark’s Oraya Therapeutics lands $42M more for Wet AMD Treatment Trial

Oraya, which now has raised $64 million in little more than two years, will use the latest round of cash to expand its clinical trials for its treatment of wet age-related macular degeneration, a common cause of blindness.

The 22-employee company’s treatment uses what it calls the IRay system, a robotically controlled, localized dose of low-energy X-ray radiation to the macula. The system is designed to be placed in almost any medical setting, the company said.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: